CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.0034
+0.0001 (3.03%)
At close: Nov 6, 2026
CERo Therapeutics Holdings Employees
CERo Therapeutics Holdings had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes CERo Therapeutics Holdings the 40,794th largest employer in the world and 6,173rd in the United States.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
258.13K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - | 8 | 0 |
| Dec 31, 2024 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2023 | 9 | - | - | 8 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyra Therapeutics | 27 |
| Altamira Therapeutics | 11 |
| Ampio Pharmaceuticals | 6 |
| Regen BioPharma | 1 |
| CNBX Pharmaceuticals | 1 |
| Actavia Life Sciences | 1 |
CERo Therapeutics Holdings News
- 4 days ago - CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial - GlobeNewsWire
- 12 days ago - CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies - GlobeNewsWire
- 12 days ago - CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers - GlobeNewsWire
- 4 months ago - CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment - GlobeNewsWire
- 6 months ago - CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial - GlobeNewsWire
- 6 months ago - CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial - GlobeNewsWire
- 7 months ago - CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial - GlobeNewsWire
- 8 months ago - Cero Therapeutics issues letter to shareholders - TheFly